Am J Psychiatry 155:921-928, July 1998
©Copyright 1998 American Psychiatric Association
5-HT2 and D2 Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Shitij Kapur, M.D., Ph.D., F.R.C.P.C.,
Robert B. Zipursky, M.D., F.R.C.P.C.,
Gary Remington, M.D., Ph.D., F.R.C.P.C.,
Corey Jones, B.Sc.,
Jean DaSilva, Ph.D.,
Alan A. Wilson, Ph.D., and
Sylvain Houle, M.D., Ph.D., F.R.C.P.C.
OBJECTIVE: Olanzapine is a new atypical antipsychotic recently introduced for the treatment of schizophrenia. The purpose of this study was to investigate olanzapine's binding to the serotonin 5-HT2 and dopamine D2 receptors in schizophrenic patients being treated with clinically relevant doses. METHOD: Twelve patients with schizophrenia were randomly assigned to 5, 10, 15, or 20 mg/day of olanzapine in a prospective fashion. Three other subjects taking 30–40 mg/day were also included. Once steady-state plasma levels were achieved, dopamine D2 and serotonin 5-HT2 receptors were assessed by using [11C]raclopride and [18F]setoperone positron emission tomography imaging, respectively. Ratings of clinical status, extrapyramidal side effects, and prolactin levels were also obtained. RESULTS: Olanzapine induced near saturation of the 5-HT2 receptors, even at 5 mg/day. Its D2 occupancy increased with dose: patients taking 5–20 mg/day showed 43%–80% D2 occupancy, while patients taking 30–40 mg/day showed 83%–88%. CONCLUSIONS: Olanzapine is a potent 5-HT2 blocker and shows a higher 5-HT2 than D2 occupancy at all doses. However, its D2 occupancy is higher than that of clozapine and similar to that of risperidone. In the usual clinical dose range of 10–20 mg/day, its occupancy varies from 71% to 80%, and this restricted range may explain its freedom from extrapyramidal side effects and prolactin elevation. However, doses of 30 mg/day and higher are associated with more than 80% D2 occupancy and may have a higher likelihood of prolactin elevation and extrapyramidal side effects. (Am J Psychiatry 1998; 155:921–928)
This article has been cited by other articles:
|
|
|
|
 
S. Ranjan, P. S Chandra, S. K Chaturvedi, S. C Prabhu, and A. Gupta
Atypical Antipsychotic-Induced Akathisia with Depression: Therapeutic Role of Mirtazapine
Ann. Pharmacother.,
April 1, 2006;
40(4):
771 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur
Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics
Am J Psychiatry,
September 1, 2004;
161(9):
1620 - 1625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al.
Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine
J Psychopharmacol,
September 1, 2004;
18(3):
355 - 365.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Mamo, S. Kapur, C. M. Shammi, G. Papatheodorou, S. Mann, F. Therrien, and G. Remington
A PET Study of Dopamine D2 and Serotonin 5-HT2 Receptor Occupancy in Patients With Schizophrenia Treated With Therapeutic Doses of Ziprasidone
Am J Psychiatry,
May 1, 2004;
161(5):
818 - 825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Blass and M. Chuen
Olanzapine-Associated Hypothermia
Psychosomatics,
April 1, 2004;
45(2):
135 - 139.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Paquet, J. P. Soucy, E. Stip, M. Levesque, A. Elie, and M. A. Bedard
Comparison Between Olanzapine and Haloperidol on Procedural Learning and the Relationship With Striatal D2 Receptor Occupancy in Schizophrenia
J Neuropsychiatry Clin Neurosci,
February 1, 2004;
16(1):
47 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Grunder, A. Carlsson, and D. F. Wong
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Arch Gen Psychiatry,
October 1, 2003;
60(10):
974 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ahmed, P. D. Mozley, and W. Z. Potter
Biomarkers in Psychotropic Drug Development
Am J Geriatr Psychiatry,
December 1, 2002;
10(6):
678 - 686.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur, R. Zipursky, C. Jones, C. S. Shammi, G. Remington, and P. Seeman
A Positron Emission Tomography Study of Quetiapine in Schizophrenia: A Preliminary Finding of an Antipsychotic Effect With Only Transiently High Dopamine D2 Receptor Occupancy
Arch Gen Psychiatry,
June 1, 2000;
57(6):
553 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. E. Duncan, S. Miyamoto, J. N. Leipzig, and J. A. Lieberman
Comparison of the Effects of Clozapine, Risperidone, and Olanzapine on Ketamine-Induced Alterations in Regional Brain Metabolism
J. Pharmacol. Exp. Ther.,
April 1, 2000;
293(1):
8 - 14.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. H. Nieman, L. J. Bour, D. H. Linszen, J. Goede, J. H. T. M. Koelman, B. P. R. Gersons, and B. W. Ongerboer de Visser
Neuropsychological and clinical correlates of antisaccade task performance in schizophrenia
Neurology,
February 22, 2000;
54(4):
866 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. N. Yatham, P. F. Liddle, J. Dennie, I-S. Shiah, M. J. Adam, C. J. Lane, R. W. Lam, and T. J. Ruth
Decrease in Brain Serotonin 2 Receptor Binding in Patients With Major Depression Following Desipramine Treatment: A Positron Emission Tomography Study With Fluorine-18-Labeled Setoperone
Arch Gen Psychiatry,
August 1, 1999;
56(8):
705 - 711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur, R. B. Zipursky, and G. Remington
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia
Am J Psychiatry,
February 1, 1999;
156(2):
286 - 293.
[Abstract]
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 1998
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
